Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-emption Limits Survive In Congress, Must Now Stare Down Supreme Court

Executive Summary

After enactment of the FDA Revitalization Act, the next challenge for trial lawyers and their allies is to see that the hard-won language on pre-emption of lawsuits is used effectively in court

You may also be interested in...



FDA Preemption: Agency’s Proposed Labeling Rule Riles Plaintiffs’ Bar

FDA's proposal to restrict when companies can revise product labeling without first getting agency approval drew a sharp reaction from lawyers involved in product liability litigation

FDA Preemption: Agency’s Proposed Labeling Rule Riles Plaintiffs’ Bar

FDA's proposal to restrict when companies can revise product labeling without first getting agency approval drew a sharp reaction from lawyers involved in product liability litigation

FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008

As 2007 came to an end, lawyers, judges and others involved in pharmaceutical litigation had just one word on their minds: preemption

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel